[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1212713A1 - 抗體的治療性用途 - Google Patents

抗體的治療性用途

Info

Publication number
HK1212713A1
HK1212713A1 HK16100631.7A HK16100631A HK1212713A1 HK 1212713 A1 HK1212713 A1 HK 1212713A1 HK 16100631 A HK16100631 A HK 16100631A HK 1212713 A1 HK1212713 A1 HK 1212713A1
Authority
HK
Hong Kong
Prior art keywords
vegfr1
antibodies
therapeutic uses
therapeutic
vegfr1 antibodies
Prior art date
Application number
HK16100631.7A
Other languages
English (en)
Inventor
Matthew Douglas Breyer
Ling Liu
Zhonghua Qi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HK1212713A1 publication Critical patent/HK1212713A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
HK16100631.7A 2013-03-15 2016-01-21 抗體的治療性用途 HK1212713A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361788870P 2013-03-15 2013-03-15
PCT/US2014/022925 WO2014150314A1 (en) 2013-03-15 2014-03-11 Therapeutic uses for vegfr1 antibodies

Publications (1)

Publication Number Publication Date
HK1212713A1 true HK1212713A1 (zh) 2016-06-17

Family

ID=50680115

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100631.7A HK1212713A1 (zh) 2013-03-15 2016-01-21 抗體的治療性用途

Country Status (16)

Country Link
US (1) US9670284B2 (zh)
EP (1) EP2970480A1 (zh)
JP (1) JP2017125013A (zh)
KR (1) KR20150119161A (zh)
CN (1) CN105102481A (zh)
AR (1) AR094919A1 (zh)
AU (1) AU2014237300B2 (zh)
BR (1) BR112015020199A2 (zh)
CA (1) CA2901509A1 (zh)
EA (1) EA201591513A1 (zh)
HK (1) HK1212713A1 (zh)
IL (1) IL241434A0 (zh)
MX (1) MX2015013066A (zh)
SG (1) SG11201507674UA (zh)
TW (1) TW201517916A (zh)
WO (1) WO2014150314A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41094A (fr) 2014-12-02 2017-10-10 Lilly Co Eli Procédés de traitement de troubles rénaux
US10364289B2 (en) 2014-12-03 2019-07-30 Samsung Life Public Welfare Foundation Antibody binding to neuropilin 1 and use thereof
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
MA41899A (fr) * 2015-04-07 2018-02-13 Shire Human Genetic Therapies Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne
US10738123B2 (en) 2015-04-07 2020-08-11 Shire Human Genetic Therapies, Inc. Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia
US10711065B2 (en) 2015-04-07 2020-07-14 Shire Human Genetic Therapies, Inc. Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia
CA3026238C (en) * 2016-06-03 2023-07-25 Samsung Life Public Welfare Foundation Anti-nrp1 antibody screening method
WO2023023465A1 (en) * 2021-08-16 2023-02-23 Janssen Biotech, Inc. Anti-vegfr1 antibodies and their uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4864900B2 (ja) 2004-11-18 2012-02-01 イムクローン・リミテッド・ライアビリティ・カンパニー 血管内皮成長因子受容体−ｉに対する抗体
CA2802726A1 (en) * 2010-06-15 2011-12-22 Medgenics Medical Israel Ltd. Long lasting drug formulations

Also Published As

Publication number Publication date
US20140271675A1 (en) 2014-09-18
JP2016511758A (ja) 2016-04-21
CA2901509A1 (en) 2014-09-25
SG11201507674UA (en) 2015-10-29
IL241434A0 (en) 2015-11-30
US9670284B2 (en) 2017-06-06
EA201591513A1 (ru) 2016-01-29
TW201517916A (zh) 2015-05-16
JP2017125013A (ja) 2017-07-20
AU2014237300A1 (en) 2015-08-20
EP2970480A1 (en) 2016-01-20
MX2015013066A (es) 2016-09-21
AU2014237300B2 (en) 2017-06-01
JP6140841B2 (ja) 2017-05-31
WO2014150314A1 (en) 2014-09-25
AR094919A1 (es) 2015-09-09
CN105102481A (zh) 2015-11-25
KR20150119161A (ko) 2015-10-23
BR112015020199A2 (pt) 2017-10-10

Similar Documents

Publication Publication Date Title
GB201321746D0 (en) Therapeutic agents
GB201321743D0 (en) Therapeutic agents
GB201321738D0 (en) Therapeutic Agents
GB201321736D0 (en) Therapeutic agents
GB201321729D0 (en) Therapeutic agents
GB201321728D0 (en) Therapeutic agents
GB201321739D0 (en) Therapeutic agents
GB201321730D0 (en) Therapeutic agents
GB201321741D0 (en) Therapeutic agents
GB201321740D0 (en) Therapeutic agents
GB201321732D0 (en) Therapeutic agents
GB201321734D0 (en) Therapeutic Agents
HK1216159A1 (zh) 治療性融合蛋白
GB201321737D0 (en) Therapeutic Agents
HK1212713A1 (zh) 抗體的治療性用途
GB201321742D0 (en) Therapeutic agents
GB201321735D0 (en) Therapeutic Agents
GB201321748D0 (en) Therapeutic agents
GB201321745D0 (en) Therapeutic agents
GB201321731D0 (en) Therapeutic agents
HK1219961A1 (zh) 人抗α型干擾素抗體
GB201308440D0 (en) Therapeutic
GB201321749D0 (en) Therapeutic agents
SI3016977T1 (sl) Humana protitelesa proti IL-32
GB201318668D0 (en) Sonosensitive therapeutic